Johnson & Johnson
Global healthcare company offering pharma, devices.
Authorization Analyst - IMPO UAM
At least three days on-site per week; up to two remote workdays. Travel may be required up to 10% domestically and internationally.
About the job
- Bachelor's degree in a relevant field, preferably with studies in Risk Management, Compliance, and Audit.
- Six to eight years of experience in user access management, particularly within an enterprise risk management framework.
- Demonstrated expertise in SAP Governance, Risk, and Compliance Access Control and Identity Management tools.
- Hands-on experience with end-to-end SAP S/4HANA implementation, including proficiency in Fiori.
- Deep knowledge of SAP authorization concepts, segregation of duties mitigation, and remediation strategies.
- Experience with risk matrix and rule-set maintenance, data analysis, conversion, and migration.
- Familiarity with Confluence, Jira, and Microsoft Teams.
- Project management capabilities and strong communication and collaboration skills.
- Proficiency in English with strong oral and written communication abilities.
- Proficiency in process management and coordination.
- Ability to work effectively in virtual or remote environments and manage cross-cultural teams.
- Strong conflict-resolution, documentation, and policy-development skills.
- Ability to work on-site at least three days per week, with up to two remote workdays.
- Ability to travel up to 10% domestically and/or internationally.
- Drive security workshops to collect business and compliance requirements for role design and validate SAP S/4HANA roles and authorization requirements after build.
- Develop user access management strategies covering composite roles, Fiori tiles, business roles, user personas, and data-security and user-interface-masking concepts for SAP S/4HANA.
- Perform data validation, conduct health checks, and provide compliance documentation.
- Design, test, and implement rule sets for SAP S/4HANA role design.
- Support role-data and user-account setup, advise on role-design testing, and coordinate business user-acceptance-testing activities.
- Manage authorization defects and support user cutover and hypercare activities.
- Collaborate with the Business Adaptation team on training, communication, and site readiness.
- Facilitate transitions between project phases and operational teams for sustained support.
- Ensure compliance with internal and external standards through SAP security assessments and audits.
- Troubleshoot and resolve SAP security issues while maintaining a secure SAP environment.
- Develop and maintain documentation for SAP security policies, procedures, and configurations.
- Train and mentor junior team members on SAP security standard processes.
- Understanding of business functions and how systems and applications are used by business partners.
- Experience in life sciences, pharmaceutical, or related industries.
- Prior experience in large-scale SAP implementation projects.
- Experience in a Project Management Office role managing activities across functional workstreams.
- Leadership ability to embrace innovation and change and promote ownership and continuous improvement.
- Ability to work with team members of varying technical expertise and communicate clearly, concisely, and tactfully with management, peers, and team members.
About the company
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- J&J raised 2026 sales guidance to $101.1 billion after July 15, 2026 results.
- TREMFYA delivered 71% growth in Q2 2026 and its first $2 billion quarter.
- Apollo’s September 2026 interest in DePuy Synthes validates a near-$20 billion asset value.
What critics are saying
- Talc litigation persists; Reuters reported a February 13, 2026 Pennsylvania loss and September 2026 settlement pressure.
- DePuy Synthes talks with Apollo on September 11, 2026 expose $9.3 billion MedTech revenue to breakup risk.
- STELARA’s biosimilar erosion still drags growth; another pipeline miss would expose J&J’s valuation.
What makes Johnson & Johnson unique
- J&J’s 2025 revenue reached $94.2 billion across pharmaceuticals, MedTech, and consumer heritage.
- Innovative Medicine holds 28 billion-dollar products, reducing dependence on any single franchise.
- TREMFYA, Carvykti, and Darzalex give J&J multiple blockbusters beyond STELARA.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -3%Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.
Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.
Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.
Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.
Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.